Skip to main content

Table 1 Demographics of study population. Median (IQR) or frequencies n (%) are shown with p-values for the group differences based on Mann-Whitney U test (a), Chi-square test (b) or Fisher’s exact test (c)

From: Rotational thrombelastometry (ROTEM) improves hemostasis assessment compared to conventional coagulation test in ACLF and Non-ACLF patients

 

Non-ACLF

n = 55

ACLF

n = 22

p-value

Age

59.0 (14.0)

56.0 (13.0)

0.42a

Male

37 (67.3%)

13 (59.1%)

0.50b

Etiology

 HCV

6 (10.9%)

1 (4.5%)

0.72c

 HBV

5 (9.1%)

2 (9.1%)

 Alcohol

28 (50.9%)

16 (72.7%)

 Autoimmune

5 (9.1%)

1 (4.5%)

 NASH

3 (5.5%)

0 (0.0%)

 others

8 (14.5%)

2 (9.1%)

Ascites grade ≥ 2

19 (34.5%)

19 (86.4%)

< 0.0001b

HE grade > 2

2 (3.6%)

9 (40.9%)

< 0.0001c

MELD score

11.0 (6.0)

25.5 (12.0)

< 0.0001a

MELD-Na+ score

12.0 (17.0)

26.0 (10.3)

< 0.0001a

Child-Pugh score

2.0 (1.0)

12.0 (3.25)

< 0.0001a

Child-Pugh class

 A

23 (41.8%)

1 (4.5%)

< 0.0001c

 B

20 (36.4%)

3 (13.6%)

 C

12 (1.8%)

18 (81.8%)

ACLF grade at admission

 0

55 (100%)

0 (0.0%)

< 0.0001c

 1

0 (0.0%)

8 (36.4%)

 2

0 (0.0%)

10 (45.5%)

 3

0 (0.0%)

4 (18.2%)

Bleeding events

3 (5.5%)

9 (40.9%)

< 0.0001c

 Variceal bleeding

0 (0.0%)

5 (55.6%)

0.21c

 Upper GI-bleeding

2 (3.6%)

1 (11.1%)

 Lower GI-bleeding

1 (1.8%)

1 (11.1%)

 Hematuria

0 (0.0%)

1 (11.1%)

 Spontaneous abdominal bleeding

0 (0.0%)

1 (11.1%)

Infectious disease

9 (16.4%)

14 (63.6%)

< 0.0001c

 Pneumonia

3 (5.5%)

6 (27.3%)

0.82c

 Urinary tract infection

1 (1.8%)

2 (9.1%)

 Bacterial peritonitis

1 (1.8%)

3 (13.6%)

 Others/unknown

5 (9.1%)

4 (18.2%)

Sepsis

0 (9.1%)

5 (22.7%)

< 0.001c

Hepatocellular carcinoma

25 (45.5%)

1 (4.5%)

< 0.0001c

Admission and Mortality

 ICU admission

7 (12.7%)

19 (86.4%)

< 0.0001c

 Length of ICU admission (d)

0.0 (0.0)

3.5 (9.3)

< 0.0001a

 Length of hospital admission (d)

6.0 (7.0)

17.0 (29.8)

< 0.0001a

 Survived ICU

7 (100%)

12 (63.2%)

< 0.0001c

 Survived hospital stay

55 (100%)

15 (68.2%)

< 0.0001b

  1. ACLF acute-on-chronic liver failure, HBV hepatitis B, HCV hepatitis C, d days, GI gastrointestinal, MELD model of end stage liver disease, HE hepatic encephalopathy, NASH non-alcoholic fatty liver disease, ICU intensive care unit, IQR interquartile range